National Institutes of Health: Depressive Disorder, Major trials

The registry lists 54 Depressive Disorder, Major studies with National Institutes of Health as lead sponsor. 9 are open to participants now and 7 have results posted.

Phase 1 6Phase 2 14Phase 3 3Phase 4 2No phase 29(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant DepressionRecruitingNCT06511908Phase 2
• Natural History of Depression, Bipolar Disorder and Suicide RiskRecruitingNCT06462196
• NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar DisorderRecruitingNCT05669703
• Defining Neurobiological Links Between Substance Use and Mental IllnessRecruitingNCT05538910Not applicable
• Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major DepressionRecruitingNCT03973268Phase 1
• Characterization and Treatment of Adolescent DepressionRecruitingNCT03388606
• Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive DisorderRecruitingNCT03065335Phase 1
• Neurobiology of SuicideRecruitingNCT02543983Phase 2
• Study of Neuro-Cognitive Correlates of Pediatric Anxiety DisordersRecruitingNCT00018057Phase 2
• Antidepressant Effects of TS-161 in Treatment-Resistant DepressionTerminatedNCT04821271Phase 2Results posted
• Phase 1 Evaluation of (2R,6R)-HydroxynorketamineCompletedNCT04711005Phase 1Results posted
• Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive DisorderCompletedNCT02484456Phase 2Results posted
• Combining Medications to Enhance Depression OutcomesCompletedNCT00590863Phase 4Results posted
• Antidepressant Effects of NR2B in Major DepressionCompletedNCT00472576Phase 1Results posted
• Lexapro and Pramipexole and to Treat Major DepressionCompletedNCT00086307Phase 2Results posted
• Rapid Antidepressant Effects of Yohimbine in Major DepressionCompletedNCT00078715Phase 2Results posted
• Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIVSuspendedNCT06705478Phase 2
• Transcranial Magnetic Stimulation for Youth With Treatment-Resistant Major Depressive DisorderWithdrawnNCT05652465Phase 2
• Transcranial Electric Stimulation Therapy (TEST) for Treatment Resistant Depression (TRD)Active, not recruitingNCT05172271Not applicable
• Concurrent fMRI-guided rTMS and Cognitive Therapy for the Treatment of Major Depressive EpisodesCompletedNCT03289923Not applicable
• PET Imaging of Brain mGluR1 Receptors Using [18F]FIMXCompletedNCT02230592
• Brain Inflammation in Major Depressive Disorder BackgroundCompletedNCT01851356
• Brain Imaging, Genetics and Treatment for Major DepressionWithdrawnNCT01568684Phase 1
• Imaging Serotonin 5HT1A Receptors in Patients With Major Depressive DisorderWithdrawnNCT01313403Not applicable
• GABA/Glutamate Balance in Temporal Lobe Epilepsy With and Without Major DepressionCompletedNCT00931619
• p11 Protein Levels in Patients With Major Depressive Disorder Treated With CitalopramCompletedNCT00697268
• Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed PatientsCompletedNCT00369798Phase 1
• Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research GroupCompletedNCT00265291Phase 2
• Integrated Treatment for Cocaine and Mood Disorders - 1CompletedNCT00227812Phase 2
• Preventing Depression in Methadone Maintenance Patients Receiving Hepatitis C Treatment - 1CompletedNCT00218556Not applicable
• Dopamine Receptor Imaging in Mood DisordersCompletedNCT00116077
• Effects of Tryptophan Depletion on Brain Processing of Emotions in Patients With Mood DisordersCompletedNCT00097175
• Neurocardiac Control in Major DepressionCompletedNCT00084162
• FMRI Study of Performance During a Probabilistic Reversal Learning Task in DepressionCompletedNCT00075296
• Evaluating Brain Responses to Facial Expressions in Major Depressive DisorderCompletedNCT00071123
• PUFA Augmentation in Treatment of Major DepressionCompletedNCT00067301Phase 3
• Brain Regulation of Emotions in People With Depression and AnhedoniaCompletedNCT00059579
• MRI Study of Brain Activity and Risk for Depression in AdolescentsCompletedNCT00047944
• Examination of a Soy-Based Supplement for Major DepressionCompletedNCT00042380Phase 2
• Clinical Trial of Memantine for Major DepressionCompletedNCT00040261Phase 3
• Serotonin Function During DepressionCompletedNCT00033787
• Riluzole to Treat Major DepressionCompletedNCT00026052Phase 2
• Brain Chemical Receptor Effects in Patients With Panic Disorder and Post-Traumatic Stress DisorderCompletedNCT00025974
• Brain Function in Mentally Ill AdolescentsCompletedNCT00025857
• Treatment for Adolescents With Depression Study (TADS)CompletedNCT00006286Phase 3
• Treatment of Major Depression With St. John's Wort (Hypericum)CompletedNCT00005013Not applicable
• Heart Disease Risk Factors in Major DepressionCompletedNCT00001969
• Use of Bone Biopsy to Better Understand the Causes of Decreased Bone Mineral Density in DepressionCompletedNCT00001916
• Dynamics of Leptin and Endocrine FunctionCompletedNCT00001543
• Bone Mineral Density in Women With Major DepressionCompletedNCT00001413
• Evaluation of the Genetics of Bipolar DisorderCompletedNCT00001174
• Study of the Psychological Development of Children of Parents With and Without Affective DisordersCompletedNCT00001170
• Omega-3 Fatty Acids in the Treatment of Bipolar Disorder: A Double-Blind, Placebo-Controlled TrialCompletedNCT00001146Phase 2
• Continuation Electroconvulsive Therapy Vs Medication to Prevent Relapses in Patients With Major Depressive DisorderCompletedNCT00000375Phase 4